Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

222
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
222
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

1.9K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
1.9K
Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

521
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
521
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

303
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
303
Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

403
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
403
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

353
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
353

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Learning to see in the gray: Strategies for building critical analysis skills in the new ambulatory care practitioner.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2025
Same author

Donanemab (Kisunla) for the Slowing of Alzheimer Disease.

American family physician·2025
Same author

Incretins for obesity: closer to a nicotine patch than a silver bullet.

Expert opinion on pharmacotherapy·2025
Same author

Lecanemab (Leqembi) for the Slowing of Alzheimer Disease.

American family physician·2025
Same author

Choose your own adventure: Perception of gamification in continuing pharmacy education.

Currents in pharmacy teaching & learning·2025
Same author

Direct Oral Anticoagulants: Probability of Recurrent Venous Thromboembolism and Bleeding Risk in an Obese Population.

The Annals of pharmacotherapy·2023

Related Experiment Video

Updated: Jul 25, 2025

Novel Apparatus and Method for Drug Reinforcement
07:32

Novel Apparatus and Method for Drug Reinforcement

Published on: August 20, 2010

19.2K

A Novel Formulation: Donepezil Patch.

Megan Adelman1, Lora Louis2

  • 11 Cleveland Clinic Akron General, Center for Family Medicine, Akron, Ohio.

The Senior Care Pharmacist
|June 29, 2023
PubMed
Summary

A new donepezil patch offers a potential treatment option for dementia, improving tolerability and aiding patients with swallowing difficulties. This formulation may reduce side effects compared to oral medications.

Area of Science:

  • Neuroscience and Pharmacology
  • Geriatric Medicine

Background:

  • Dementia prevalence is rising globally, necessitating improved therapeutic strategies.
  • Acetylcholinesterase inhibitors are primary pharmacotherapy for dementia, with oral agents like donepezil, galantamine, and rivastigmine widely used.
  • Existing oral formulations present challenges, including potential side effects and administration difficulties for some patients.

Purpose of the Study:

  • To review the efficacy, safety, and tolerability of a novel donepezil patch formulation.
  • To explore clinical considerations for utilizing the new donepezil patch in dementia management.
  • To assess the potential benefits for patients with dysphagia and reduced side effect burden.

Main Methods:

  • Literature review and analysis of available clinical data.

More Related Videos

2-Methacryloyloxyethyl Phosphorylcholine Polymer Treatment of Complete Dentures to Inhibit Denture Plaque Deposition
06:02

2-Methacryloyloxyethyl Phosphorylcholine Polymer Treatment of Complete Dentures to Inhibit Denture Plaque Deposition

Published on: December 26, 2016

10.4K
Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
07:49

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Published on: September 17, 2014

11.6K

Related Experiment Videos

Last Updated: Jul 25, 2025

Novel Apparatus and Method for Drug Reinforcement
07:32

Novel Apparatus and Method for Drug Reinforcement

Published on: August 20, 2010

19.2K
2-Methacryloyloxyethyl Phosphorylcholine Polymer Treatment of Complete Dentures to Inhibit Denture Plaque Deposition
06:02

2-Methacryloyloxyethyl Phosphorylcholine Polymer Treatment of Complete Dentures to Inhibit Denture Plaque Deposition

Published on: December 26, 2016

10.4K
Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
07:49

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Published on: September 17, 2014

11.6K
  • Comparative assessment of the novel donepezil patch versus oral formulations.
  • Evaluation of safety profiles, including adverse events and tolerability.

    • Main Results:

    • The donepezil patch demonstrates comparable efficacy to oral donepezil.
    • The patch formulation may offer improved tolerability and a reduced incidence of certain gastrointestinal side effects.
    • It provides a viable alternative for patients experiencing dysphagia.

    Conclusions:

    • The novel donepezil patch represents a significant advancement in dementia pharmacotherapy.
    • This formulation enhances treatment options by addressing administration challenges and potentially improving patient adherence and outcomes.
    • Further research should focus on long-term efficacy and real-world effectiveness.